An Alzheimer's drug developed by Swiss company Roche could not be proven in clinical trials to slow the progression of dementia, the pharmaceutical giant said Monday.
In a statement, Roche said the drug, gantenerumab, "did not meet their primary endpoint of slowing clinical decline" in a pair of studies conducted by the company. The identical studies, which were conducted with patients over the course of two years, were held in an effort to prove that gantenerumab could preserve certain functions in early Alzheimer's patients, including problem-solving skills, memory, and judgment.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Foreigners in Spain facing a 100% tax on homes as the country battles a housing crisisUnder the Radar The goal is to provide 'more housing, better regulation and greater aid,' said Spain's prime minister
-
Codeword: January 22, 2025The Week's daily codeword puzzle
-
Sudoku medium: January 22, 2025The Week's daily medium sudoku puzzle
-
The UK's first legal drug consumption roomThe Explainer 'Potentially transformative moment in UK drugs policy' as The Thistle opens in Glasgow
-
What are the long-term effects of alcohol?It's not just cancer
-
How close are we to a norovirus vaccine?Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
-
Kidney stones are affecting children far more than they once didUnder the radar Salt may be to blame
-
Walking pneumonia cases are picking up paceThe explainer Another respiratory illness to be wary of
-
Drugmakers paid pharmacy benefit managers to avoid restricting opioid prescriptionsUnder the radar The middlemen and gatekeepers of insurance coverage have been pocketing money in exchange for working with Big Pharma
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
-
Bird flu one mutuation from human threat, study findsSpeed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
